TN2015000490A1 - Dérivés d'imidazo-triazine servant d' inhibiteurs de pde10 - Google Patents
Dérivés d'imidazo-triazine servant d' inhibiteurs de pde10Info
- Publication number
- TN2015000490A1 TN2015000490A1 TN2015000490A TN2015000490A TN2015000490A1 TN 2015000490 A1 TN2015000490 A1 TN 2015000490A1 TN 2015000490 A TN2015000490 A TN 2015000490A TN 2015000490 A TN2015000490 A TN 2015000490A TN 2015000490 A1 TN2015000490 A1 TN 2015000490A1
- Authority
- TN
- Tunisia
- Prior art keywords
- imidazo
- triazine derivatives
- pde10 inhibitors
- pde10
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical class N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003918 triazines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne une classe nouvelle de dérivés de triazine tels que décrits par la formule (I) ci-dessous dans laquelle A, X, R1, R2, R3, et R4 sont tels que définis dans le présent mémoire et l'utilisation des composés comme inhibiteurs de la PDE10.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818650P | 2013-05-02 | 2013-05-02 | |
| PCT/IB2014/060945 WO2014177977A1 (fr) | 2013-05-02 | 2014-04-23 | Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2015000490A1 true TN2015000490A1 (fr) | 2017-04-06 |
Family
ID=50841902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2015000490A TN2015000490A1 (fr) | 2013-05-02 | 2014-04-23 | Dérivés d'imidazo-triazine servant d' inhibiteurs de pde10 |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US8933224B2 (fr) |
| EP (1) | EP2991989B1 (fr) |
| JP (1) | JP6263606B2 (fr) |
| KR (1) | KR101770905B1 (fr) |
| CN (1) | CN105164134B (fr) |
| AP (1) | AP2015008843A0 (fr) |
| AR (1) | AR096161A1 (fr) |
| AU (1) | AU2014261070A1 (fr) |
| BR (1) | BR112015027760A8 (fr) |
| CA (1) | CA2910759C (fr) |
| CL (1) | CL2015003037A1 (fr) |
| CR (1) | CR20150591A (fr) |
| CU (1) | CU20150144A7 (fr) |
| DK (1) | DK2991989T3 (fr) |
| DO (1) | DOP2015000271A (fr) |
| EA (1) | EA027936B1 (fr) |
| EC (1) | ECSP15050110A (fr) |
| ES (1) | ES2637816T3 (fr) |
| GE (1) | GEP201706675B (fr) |
| MA (1) | MA38559B1 (fr) |
| MD (1) | MD20150103A2 (fr) |
| MX (1) | MX2015015163A (fr) |
| NI (1) | NI201500157A (fr) |
| NZ (1) | NZ712949A (fr) |
| PE (1) | PE20151940A1 (fr) |
| PH (1) | PH12015502462A1 (fr) |
| SG (1) | SG11201508201VA (fr) |
| TN (1) | TN2015000490A1 (fr) |
| TW (1) | TWI508966B (fr) |
| UA (1) | UA111696C2 (fr) |
| UY (1) | UY35547A (fr) |
| WO (1) | WO2014177977A1 (fr) |
| ZA (1) | ZA201508968B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP201706675B (en) * | 2013-05-02 | 2017-05-25 | Pfizer | Imidazo-triazine derivatives as pde10 inhibitors |
| WO2018047081A1 (fr) | 2016-09-09 | 2018-03-15 | Novartis Ag | Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal |
| CA3102598A1 (fr) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 |
| JP7212781B2 (ja) | 2018-12-19 | 2023-01-25 | ディスアーム セラピューティクス， インコーポレイテッド | 神経保護剤と組み合わせたｓａｒｍ１の阻害剤 |
| MX2022004741A (es) * | 2019-10-21 | 2022-05-16 | Sk Biopharmaceuticals Co Ltd | Uso de compuestos de imidazopirimidina o imidazotriazina para prevencion, alivio, o tratamiento de trastornos cognitivos, o para mejorar la funcion cognitiva. |
| CN117486878A (zh) * | 2023-10-27 | 2024-02-02 | 扬州市普林斯医药科技有限公司 | 一种恩那司他的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| DE10130167A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
| CA2534432A1 (fr) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a |
| JP4559749B2 (ja) * | 2004-02-16 | 2010-10-13 | あすか製薬株式会社 | ピペラジニルピリジン誘導体 |
| EP1595881A1 (fr) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine |
| US20070167426A1 (en) | 2004-06-02 | 2007-07-19 | Schering Corporation | Compounds for the treatment of inflammatory disorders and microbial diseases |
| TW200716102A (en) | 2005-06-01 | 2007-05-01 | Wyeth Corp | Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors |
| US20080051419A1 (en) | 2006-07-26 | 2008-02-28 | Pfizer Inc. | Amine derivatives useful as anticancer agents |
| JP5274256B2 (ja) | 2006-09-26 | 2013-08-28 | 株式会社カネカ | 光学活性β−ヒドロキシ−α−アミノカルボン酸エステルの製造方法 |
| WO2008057402A2 (fr) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines et composés associés servant d'activateurs de caspases et d'inducteurs d'apoptose et leur utilisation |
| WO2009025785A2 (fr) | 2007-08-21 | 2009-02-26 | Merck & Co., Inc. | Ligands de récepteur cb2 pour le traitement de la douleur |
| DE102007059723A1 (de) | 2007-12-12 | 2009-06-18 | Siemens Medical Instruments Pte. Ltd. | Hörvorrichtung mit Batterieklappenmodul |
| PE20091057A1 (es) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
| MX2010010151A (es) | 2008-03-20 | 2010-10-25 | Amgen Inc | Moduladores de cinasa aurora y metodo de uso. |
| US20120220581A1 (en) * | 2009-10-30 | 2012-08-30 | Janssen-Cilag, S.A. | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| US9073927B2 (en) | 2010-01-22 | 2015-07-07 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Inhibitors of PI3 kinase |
| AR080754A1 (es) * | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| WO2011141713A1 (fr) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Nouveaux composés bicycliques en tant qu'inhibiteurs de pi3-k et de mtor |
| KR20130083389A (ko) | 2010-05-28 | 2013-07-22 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 야누스 키나아제 억제제로서 헤테로사이클릭 화합물 |
| EP2582681A1 (fr) | 2010-06-17 | 2013-04-24 | Novartis AG | Dérivés de 1,3 dihydro-benzoimidazol-2-ylidène-amine à substitution pipéridinyle |
| EA022586B1 (ru) * | 2011-02-23 | 2016-01-29 | Пфайзер Инк. | ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ |
| GEP201706675B (en) * | 2013-05-02 | 2017-05-25 | Pfizer | Imidazo-triazine derivatives as pde10 inhibitors |
-
2014
- 2014-04-23 GE GEAP201413979A patent/GEP201706675B/en unknown
- 2014-04-23 UA UAA201510060A patent/UA111696C2/uk unknown
- 2014-04-23 AP AP2015008843A patent/AP2015008843A0/xx unknown
- 2014-04-23 DK DK14727054.0T patent/DK2991989T3/en active
- 2014-04-23 CN CN201480024798.1A patent/CN105164134B/zh not_active Expired - Fee Related
- 2014-04-23 MA MA38559A patent/MA38559B1/fr unknown
- 2014-04-23 MD MDA20150103A patent/MD20150103A2/ro not_active Application Discontinuation
- 2014-04-23 EP EP14727054.0A patent/EP2991989B1/fr active Active
- 2014-04-23 WO PCT/IB2014/060945 patent/WO2014177977A1/fr not_active Ceased
- 2014-04-23 SG SG11201508201VA patent/SG11201508201VA/en unknown
- 2014-04-23 NZ NZ712949A patent/NZ712949A/en not_active IP Right Cessation
- 2014-04-23 JP JP2016511150A patent/JP6263606B2/ja not_active Expired - Fee Related
- 2014-04-23 EA EA201591819A patent/EA027936B1/ru not_active IP Right Cessation
- 2014-04-23 TN TN2015000490A patent/TN2015000490A1/fr unknown
- 2014-04-23 BR BR112015027760A patent/BR112015027760A8/pt not_active Application Discontinuation
- 2014-04-23 PE PE2015002303A patent/PE20151940A1/es not_active Application Discontinuation
- 2014-04-23 KR KR1020157034216A patent/KR101770905B1/ko not_active Expired - Fee Related
- 2014-04-23 CA CA2910759A patent/CA2910759C/fr not_active Expired - Fee Related
- 2014-04-23 MX MX2015015163A patent/MX2015015163A/es unknown
- 2014-04-23 ES ES14727054.0T patent/ES2637816T3/es active Active
- 2014-04-23 AU AU2014261070A patent/AU2014261070A1/en not_active Abandoned
- 2014-04-29 TW TW103115365A patent/TWI508966B/zh not_active IP Right Cessation
- 2014-04-30 UY UY0001035547A patent/UY35547A/es not_active Application Discontinuation
- 2014-04-30 AR ARP140101792A patent/AR096161A1/es unknown
- 2014-04-30 US US14/265,458 patent/US8933224B2/en not_active Expired - Fee Related
- 2014-11-21 US US14/549,871 patent/US9145427B2/en not_active Expired - Fee Related
-
2015
- 2015-08-19 US US14/829,842 patent/US9296761B2/en not_active Expired - Fee Related
- 2015-10-13 CL CL2015003037A patent/CL2015003037A1/es unknown
- 2015-10-19 CU CUP2015000144A patent/CU20150144A7/es unknown
- 2015-10-23 PH PH12015502462A patent/PH12015502462A1/en unknown
- 2015-10-27 CR CR20150591A patent/CR20150591A/es unknown
- 2015-10-30 NI NI201500157A patent/NI201500157A/es unknown
- 2015-11-02 DO DO2015000271A patent/DOP2015000271A/es unknown
- 2015-11-30 EC ECIEPI201550110A patent/ECSP15050110A/es unknown
- 2015-12-01 ZA ZA2015/08968A patent/ZA201508968B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33275B1 (fr) | Inhibiteurs de la replication du virus de l'immunodeficience humaine | |
| TN2015000490A1 (fr) | Dérivés d'imidazo-triazine servant d' inhibiteurs de pde10 | |
| MA37756A1 (fr) | Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane | |
| MA35434B1 (fr) | Amino-quinazolines en tant qu'inhibiteurs de kinase | |
| MA42109A (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| MA38432A1 (fr) | Nouveaux dérivés d'octahydro-pyrrolo [3,4-c]-pyrrole et analogues de ceux-ci servant d'inhibiteurs d'autotaxine | |
| MA35664B1 (fr) | Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one | |
| MA35357B1 (fr) | Composes de type anilines | |
| WO2019035863A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques | |
| MA34644B1 (fr) | Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2 | |
| MA38403A1 (fr) | Nouveaux dérivés de pyrazole modulateurs specifiques de cb2 | |
| PE20181378A1 (es) | Compuestos biciclicos derivados de dihidroquinolina-2-ona como inhibidores de cyp11b | |
| MA38404A1 (fr) | Nouveaux dérivés de pyridine | |
| MA39317A1 (fr) | Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe | |
| MA35364B1 (fr) | Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire | |
| TN2015000347A1 (fr) | Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles | |
| MA39152A1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| MA38112A1 (fr) | Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa | |
| MA40302B1 (fr) | Dérivés de carbazole | |
| MA35663B1 (fr) | Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2 | |
| MA38948B1 (fr) | Dérivés de 2h-indazole antibactériens | |
| MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
| MA37384B1 (fr) | Nouveaux dérivés de thiénopyrimidine, leurs procédés de préparation et leurs utilisations thérapeutiques. | |
| MA32985B1 (fr) | Nouveaux microbiocides | |
| MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer |